A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Duvelisib (Primary) ; Ofatumumab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms DUO
- Sponsors Infinity Pharmaceuticals; Verastem
- 17 Oct 2017 Results presented in a Verastem media release.
- 17 Oct 2017 According to a Verastem media release, Verastem pays a $6 million milestone to Infinity Pharmaceuticals based on the achievement of positive top-line results of this trial.
- 06 Sep 2017 Primary endpoint of Progression-free survival has been met, according to results published in a Verastem Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History